FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792674364> ?p ?o ?g. }

• W2792674364 abstract "TPS713 Background: Human Myeloid Derived Suppressor Cells (MDSCs) have gained recognition as a significant population of cells that arise in cancer patients to mediate immune tolerance. Some studies have shown MDSC concentrations to be associated with overall survival and response to therapy in renal cell carcinoma. MDSCs comprise a heterogenous population that are yet to be fully characterized. We have identified a set of biomarkers uniquely expressed by the suppressive human MDSC phenotype and have developed an assay targeted to these markers. MDSCs are potentially a relatively cheap and easily performed screening and monitoring tool in cancers. This study will examine how a proprietary clinical assay works in detecting and monitoring MDSCs in blood and urine samples from patients with localized or metastatic renal cell cancer. Methods: The pilot research trial will enroll 63 subjects in a 1:1:1 ratio in three groups, normal controls over age 40 without evidence of any malignancy, patients with metastatic disease and localized renal cell carcinoma prior to nephrectomy. This sample size provides 80% power to detect a 1SD difference in MDSC concentrations in these groups on an F test. Blood and urine samples will be drawn at baseline and at 4 months for comparison. The percent CD33+ HLA-DRlow HIF1a+, CD33+ HLADRlow C/EBPb+, CD11b+ HLA-DRlow HIF1a+, and CD11b+ HLA-DRlow C/EBPb+cells as a fraction of PBMC will be determined. Primary Outcome Measures will be 1. Change in MDSC levels in patients with known localized renal cell carcinoma who undergo surgical treatment. 2. Change in MDSC level in patients with known metastatic renal cell carcinoma who initiate systemic treatment and 3. The direction and magnitude of the changes compared with radiographically assessed tumor burden. Secondary outcome measures are to assess MDSC level measurements in urine cytology analysis at baseline and after treatment to determine whether the two tests correlate in any of the 3 groups of patients defined in this study. Conclusion: This pilot study will examine if a MDSC clinical assay works in detecting and monitoring MDSCs. Recruitment is open to patients at the USC Cancer center and LAC+USC medical center. Clinical trial information: NCT02664883." @default.
• W2792674364 created "2018-03-29" @default.
• W2792674364 creator A5012631223 @default.
• W2792674364 creator A5019454857 @default.
• W2792674364 creator A5020125488 @default.
• W2792674364 creator A5030448517 @default.
• W2792674364 creator A5047212274 @default.
• W2792674364 creator A5077143749 @default.
• W2792674364 creator A5077391800 @default.
• W2792674364 creator A5077696148 @default.
• W2792674364 date "2018-02-20" @default.
• W2792674364 modified "2023-09-23" @default.
• W2792674364 title "MDSC clinical assay for cancer detection and monitoring in renal cell carcinoma." @default.
• W2792674364 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.tps713" @default.
• W2792674364 hasPublicationYear "2018" @default.
• W2792674364 type Work @default.
• W2792674364 sameAs 2792674364 @default.
• W2792674364 citedByCount "0" @default.
• W2792674364 crossrefType "journal-article" @default.
• W2792674364 hasAuthorship W2792674364A5012631223 @default.
• W2792674364 hasAuthorship W2792674364A5019454857 @default.
• W2792674364 hasAuthorship W2792674364A5020125488 @default.
• W2792674364 hasAuthorship W2792674364A5030448517 @default.
• W2792674364 hasAuthorship W2792674364A5047212274 @default.
• W2792674364 hasAuthorship W2792674364A5077143749 @default.
• W2792674364 hasAuthorship W2792674364A5077391800 @default.
• W2792674364 hasAuthorship W2792674364A5077696148 @default.
• W2792674364 hasConcept C121608353 @default.
• W2792674364 hasConcept C126322002 @default.
• W2792674364 hasConcept C143998085 @default.
• W2792674364 hasConcept C2777472916 @default.
• W2792674364 hasConcept C2777546739 @default.
• W2792674364 hasConcept C2781068499 @default.
• W2792674364 hasConcept C502942594 @default.
• W2792674364 hasConcept C71924100 @default.
• W2792674364 hasConceptScore W2792674364C121608353 @default.
• W2792674364 hasConceptScore W2792674364C126322002 @default.
• W2792674364 hasConceptScore W2792674364C143998085 @default.
• W2792674364 hasConceptScore W2792674364C2777472916 @default.
• W2792674364 hasConceptScore W2792674364C2777546739 @default.
• W2792674364 hasConceptScore W2792674364C2781068499 @default.
• W2792674364 hasConceptScore W2792674364C502942594 @default.
• W2792674364 hasConceptScore W2792674364C71924100 @default.
• W2792674364 hasLocation W27926743641 @default.
• W2792674364 hasOpenAccess W2792674364 @default.
• W2792674364 hasPrimaryLocation W27926743641 @default.
• W2792674364 hasRelatedWork W1577847722 @default.
• W2792674364 hasRelatedWork W1955759569 @default.
• W2792674364 hasRelatedWork W1976310228 @default.
• W2792674364 hasRelatedWork W2019017329 @default.
• W2792674364 hasRelatedWork W2040986265 @default.
• W2792674364 hasRelatedWork W2051998002 @default.
• W2792674364 hasRelatedWork W2099402024 @default.
• W2792674364 hasRelatedWork W2101015190 @default.
• W2792674364 hasRelatedWork W2372137915 @default.
• W2792674364 hasRelatedWork W2597962907 @default.
• W2792674364 hasRelatedWork W2800539020 @default.
• W2792674364 hasRelatedWork W2808333550 @default.
• W2792674364 hasRelatedWork W2942690033 @default.
• W2792674364 hasRelatedWork W2984186351 @default.
• W2792674364 hasRelatedWork W3014003047 @default.
• W2792674364 hasRelatedWork W3046152640 @default.
• W2792674364 hasRelatedWork W3086616785 @default.
• W2792674364 hasRelatedWork W3115374815 @default.
• W2792674364 hasRelatedWork W3127734769 @default.
• W2792674364 hasRelatedWork W3173306083 @default.
• W2792674364 isParatext "false" @default.
• W2792674364 isRetracted "false" @default.
• W2792674364 magId "2792674364" @default.
• W2792674364 workType "article" @default.